The mission of Dana-Farber Cancer Institute is to provide expert, compassionate care to children and adults with cancer while advancing the understanding, diagnosis, treatment, cure, and prevention of cancer and related disease.
The Pharmacy department maintains programs and practices to ensure safe, optimal, and cost effective drug therapy for Dana-Farber patients, while also supporting patient and provider drug education and patient care-oriented research.
The Pharmacy Residency Program is an ASHP-accredited PGY-2 oncology pharmacy residency designed to provide the resident with opportunities to develop clinical competence in oncology pharmacy practice. Residents are exposed to a multitude of experiences related to cancer care, involving inpatient care at Brigham and Women's Hospital, and ambulatory-related experiences at Dana-Farber Cancer Institute. The resident will gain experience in the following areas of practice:
Through these educational experiences, residents will:
Dana-Farber Cancer Institute’s PGY-2 oncology pharmacy residency program gives the residents many opportunities to co-precept and lecture students at the affiliated schools of pharmacy. The residency is primarily affiliated with two schools of pharmacy, including Northeastern School of Pharmacy and Massachusetts College of Pharmacy and Health Sciences University - Boston.
Research projects will be determined according to the resident's interest and department needs. The resident will be required to complete one project to be presented at a national meeting (HOPA).
Examples of past resident research projects:
Pharmacy residents will receive a competitive stipend for the PGY-2 residency year. Other benefits include, but are not limited to, medical and dental coverage, and MBTA discount passes.
In addition, pharmacy residents will be invited to attend professional conferences, including:
Dana-Farber Cancer Institute is a major affiliate of Harvard Medical School that is a designated National Comprehensive Cancer Center (NCCN) by the National Cancer Institute. Dana-Farber partners with Brigham and Women’s Hospital to care for adults with cancer, and partners with Boston Children’s Hospital to provide cancer care for children.
U.S. News &World Report's Best Hospitals Guide has consistently ranked Dana-Farber/Brigham and Women's Cancer Center the highest in New England for adult cancer care, while Dana-Farber/Boston Children's Cancer and Blood Disorders Center is the nation's #1-ranked pediatric cancer program, according to U.S. News & World Report's 2014-15 Best Children's Hospitals report.
In addition, the Quality Oncology Practice Initiative (QOPI®) Certification Program, an affiliate of the American Society of Clinical Oncology (ASCO), has awarded Dana-Farber Cancer Institute a three-year certification for outpatient hematology-oncology practices that meet its highest standards for quality cancer care.
Learn more about Dana-Farber’s awards and honors.
The resident will spend approximately ten months completing core rotations, and is allotted two months for elective experiences and research.
Bridget Fowler Scullion, PharmD, BCOPClinical Pharmacy ManagerEducation: St. Louis College of PharmacyPGY-2 Training: University of Maryland, School of Pharmacy, Baltimore, MD
Sylvia B. Bartel, RPh, MHPVice President of Pharmacy ServicesEducation: University of Wisconsin, Madison, WIPGY-1 Training: National Institutes of Health, Clinical Center, Bethesda, MD
Christy S. Harris, PharmD, BCPS, BCOPAssociate Professor – MCPHS University, Clinical Pharmacy SpecialistEducation: University of Tennessee Health Sciences, Memphis, TNPGY-1 Training: University of Tennessee Medical Center, Knoxville, TNPGY-2 Training: Medical University of South Carolina, Charleston, SC
Anne McDonnell, PharmD, BCOPInpatient Clinical Pharmacy SpecialistBS: MCPHS University - BostonPharmD: University of Arkansas for Medical SciencesPGY-1 Training: New York Presbyterian Hospital, New York, NYPGY-2 Training: Medical University of South Carolina, Charleston, SC
Caroline Harvey, RPhResearch Pharmacy ManagerEducation: Northeastern University, Boston, MA
Andrew Skirvin, BS, PharmD, BCOPAssociate Clinical Professor – Northeastern University, Hematology/Oncology Clinical PharmacistEducation: University of Texas Health Science Center (PharmD) and Oregon State University (BS)PGY-2 Training: Audie L. Murphy Memorial VA Hospital, San Antonio, TX
Audrea Szabatura, PharmD, BCOPMedication Safety OfficerEducation: University of ConnecticutPGY-1 Training: Thomas Jefferson University Hospital, Philadelphia, PAPGY-2 Training: The Johns Hopkins Hospital, Baltimore, MD
Victor Phantumvanit, PharmD, BCPs, BCOPClinical Pharmacy SpecialistEducation: University of Maryland, School of Pharmacy, Baltimore, MDPGY-1 Training: Central Washington Hospital, Wenatchee, WAPGY-2 Training: Dana-Farber Cancer Institute, Boston, MA
Theresa LeFrancois, PharmD, BCOPPediatric Oncology Clinical PharmacistEducation: Massachusetts College of Pharmacy and Health Sciences, Boston, MA
Pharm.D degree and ASHP accredited PGY1 pharmacy residency required, with experience in oncology preferred. Candidate must also be eligible for licensure in the Commonwealth of Massachusetts.
Please submit your application through PhORCAS — https://portal.phorcas.org/:
Deadline for applying: First Friday in JanuaryResidency start date: First Monday following the 4th of July holiday
For more information, please contact:
Bridget Fowler Scullion, PharmD, BCOPResidency Program Director / Clinical Pharmacy Managerbridget_scullion@dfci.harvard.edu
Sylvia Bartel, RPh, MHPVice President of Pharmacysylvia_bartel@dfci.harvard.edu
Search by last name:
Browse directory of
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 | Call us toll-free: